New hope for frail seniors with head and neck cancer: easier treatment regimen tested
NCT ID NCT06998069
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a milder combination of chemotherapy, immunotherapy, and radiation for adults aged 65 and older with head and neck cancer who are considered frail. The goal is to see if more patients can complete the full treatment course. The regimen is tailored based on a biomarker (PD-L1 CPS) and aims to control the disease while being easier to tolerate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin, Paclitaxel, Pembrolizumab, Cetuximab, and Radiation Therapy
What this could lead to
If successful, this could offer a gentler, effective treatment option for older adults with head and neck cancer who are too frail for standard therapy.
What could go wrong
This is a very small early-phase trial (20 participants) testing a reduced-intensity regimen. It may not work as well as standard treatment, and side effects from chemo, immunotherapy, and radiation are still possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Rhode Island and The Miriam Hospitals
RECRUITINGProvidence, Rhode Island, 02903/02906, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact